Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy

References

• Ali MF, Salah M, Rafea M, Saleh N. 2008. Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med Sci Monit. 14:PI66–74.
   Web of Science ®Google Scholar
• Almutawa F, Alnomair N, Wang Y, Hamzavi I, Lim HW. 2013. Systematic review of UV-based therapy for psoriasis. Am J Clin Dermatol. 14:87–109.
   PubMed Web of Science ®Google Scholar
• Azeem A, Khan ZI, Aqil M, Ahmad FJ, Khar RK, Talegaonkar S. 2009. Microemulsions as a surrogate carrier for dermal drug delivery. Drug Dev Ind Pharm. 35:525–547.
   PubMed Web of Science ®Google Scholar
• Brady SP. 2004. Parakeratosis. J Am Acad Dermatol. 50:77–84.
   PubMedGoogle Scholar
• Dayal S, Jain VK. 2010. Comparative evaluation of NBUVB phototherapy and PUVA photochemotherapy in chronic plaque psoriasis. Indian J Dermatol Venereol Leprol. 76:533–537.
   PubMed Web of Science ®Google Scholar
• Dogra S, Krishna V, Kanwar AJ. 2012. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study. Clin Exp Dermatol. 37:729–734.
   PubMed Web of Science ®Google Scholar
• Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. 2007. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release. 123:148–154.
   PubMed Web of Science ®Google Scholar
• Garg T, Singh O, Arora S, Murthy R. 2012. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst. 29:1–63.
   PubMed Web of Science ®Google Scholar
• Hashizume H, Ito T, Yagi H, Takigawa M, Kageyama H, Furukawa F, et al. 2007.Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris. J Dermatol. 34:430–434.
   PubMed Web of Science ®Google Scholar
• Ko YT, Bickel U. 2012. Liposome-encapsulated polyethylenimine/oligonucleotide polyplexes prepared by reverse-phase evaporation technique. AAPS PharmSciTech. 13:373–378.
   PubMed Web of Science ®Google Scholar
• Kocak AY, Kocak O, Aslan F, Tektas M. 2013. Methotrexate toxicity presenting as cutaneous ulcerations on psoriatic plaques. Cutan Ocul Toxicol. 32:333–335.
   PubMed Web of Science ®Google Scholar
• Lotti TM. 2008.Dermatologic therapy issue on “New and emerging treatments in dermatology”, Dermatol Ther. 21:85.
   Google Scholar
• Lunter D, Daniels R. 2013. In vitro skin permeation and penetration of nonivamide from novel film-forming emulsions. Skin Pharmacol Physiol. 26:139–146.
   PubMed Web of Science ®Google Scholar
• Mason AR, Mason J, Cork M, Dooley G, Hancock H. 2013. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 3: CD005028.
   PubMedGoogle Scholar
• Nagle A, Goyal AK, Kesarla R, Murthy RR. 2011. Efficacy study of vesicular gel containing methotrexate and menthol combination on parakeratotic rat skin model. J Liposome Res. 21:134–140.
   PubMed Web of Science ®Google Scholar
• Sebok B, Bonnekoh B, Kerenyi M, Gollnick H. 2000. Tazarotene induces epidermal cell differentiation in the mouse tail test used as an animal model for psoriasis. Skin Pharmacol Appl Skin Physiol. 13:285–291.
   PubMedGoogle Scholar
• Shirsand S, Para M, Nagendrakumar D, Kanani K, Keerthy D. 2012. Formulation and evaluation of Ketoconazole niosomal gel drug delivery system. Int J Pharm Investig. 2:201–207.
   PubMedGoogle Scholar
• Silva FS, Oliveira H, Moreiras A, Fernandes JC, Bronze-da-Rocha E, Figueiredo A, et al. 2013. Cytotoxic and genotoxic effects of acitretin, alone or in combination with psoralen-ultraviolet A or narrow-band ultraviolet B-therapy in psoriatic patients, Mutat Res. 753:42–47.
   PubMedGoogle Scholar
• Ruchusatsawat K, Wongpiyabovorn J, Protjaroen P, Chaipipat M, Shuangshoti S, Thorner PS, Mutirangura A. 2011. Parakeratosis in skin is associated with loss of inhibitor of differentiation 4 via promoter methylation. Hum Pathol. 42:1878–1887.
   PubMedGoogle Scholar